Navigation Links
VIVUS to Present at the Needham and Company Life Sciences Conference
Date:6/3/2009

MOUNTAIN VIEW, Calif., June 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Dr. Barbara Troupin, senior director clinical development, will present an overview of the company at the 8th Annual Needham Life Sciences Conference.

The VIVUS presentation will take place at the New York Palace Hotel on Thursday, June 11, 2009 at 3:30 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/needham31/vvus/ or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations:  The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200
                               Media Relations:     Pure Communications, Inc.
                                                    Sheryl Seapy
                                                    949-608-0841


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... Rocky Mountain Hobby-Expo in Denver, Colorado October 28 and 29, 2017, to promote ... event is to promote participation in different hobbies, including but not limited to ...
(Date:9/21/2017)... ... (PRWEB) September 21, 2017 , ... The 3rd World Congress ... the latest knowledge on these products, which are increasingly used in crop production ... of Biostimulants on Plant Nutrition, Abiotic Stresses, Plant Growth and Development, as well ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... this month, the response was swift and efficient thanks to the continuing efforts ... is made up of more than 50 stakeholders, including officials from area counties ...
(Date:9/20/2017)... Haven, CT (PRWEB) , ... September 20, 2017 ... ... company, announced today that it has appointed Vishwas Paralkar to the role of ... Cybrexa’s tumor targeting technology. He will report to Cybrexa’s president and CEO, Per ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):